Introduction
Infectious diseases are causally related to a large array of non-communicable diseases (NCDs). Identifying genetic determinants of infections and antibody-mediated immune responses may shed light on this relationship and provide therapeutic targets for drug and vaccine development.
Methods
We used the UK biobank cohort of up to 10,000 serological measurements of infectious diseases and genome-wide genotyping. We used data on 13 pathogens to define 46 phenotypes: 15 seropositivity case-control phenotypes, and 31 quantitative antibody measurement phenotypes. For each of these, we performed genome-wide association studies (GWAS) using the fastGWA linear mixed model package, and human leukocyte antigen (HLA) classical allele and amino acid residue associations analyses using Lasso regression for variable selection.
Results
We included a total of 8735 individuals for case-control phenotypes, and an average of 4286 samples per quantitative analyses (range: 276 to 8555). Fourteen of the GWAS yielded a genome-wide significant (p<5x10 -8) loci at the major histocompatibility complex (MHC) on chromosome 6. Outside the MHC, we found a total of 60 loci, multiple associated with Epstein-Barr virus (EBV) related NCDs (e.g. RASA3, MED12L, and IRF4). FUT2 was also identified as an important gene for polyomaviridae. HLA analysis highlighted the importance DRB1*09:01, DQB1*02:01, DQA1*01:02, and DQA1*03:01 in EBV serologies, and of DRB1*15:01 in polyomaviridae.
Conclusion
We have identified multiple genetic variants associated with antibody immune response to 13 infections, many of which are biologically plausible therapeutic or vaccine targets. This may help prioritize future research and drug development.